SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (942)12/19/1997 10:39:00 AM
From: Scott Pratho  Read Replies (1) | Respond to of 1359
 
NeuroInvestment,

Thanks for the complimentory copy of NeuroInvestment and NeuroPractice. I especially enjoyed your article "The Next Generation of Stroke Drugs: 1998." I am excited about citicoline since we currently have little to offer acute ischemic stroke patients. The vast majority of them just do not meet the criteria for tPA. It appears from your article that citicoline will have little, if any, competition. I also believe, like you, that "the burden of justification will shift to why one would not use citicoline in a case of ischemic stroke." There will probably be a lot of "CYA" prescribing. Possibly crossover prescribing for TIA's (maybe dementia??). With this in mind what do you think the U.S. market will be for citicoline?

Thanks again,
Scott Pratho
ER Doc



To: NeuroInvestment who wrote (942)12/19/1997 1:24:00 PM
From: WeirdPro Randy  Read Replies (1) | Respond to of 1359
 
NeuroInvestment,
Could you give any information on the IPIC study being done on Redux esp. when this might be completed?
Also, will this study and / or the AHP study also go into more detail, ie give "sub-group" information of valvular disease incidence based on dosage, duration of use,etc., as well as give specifics on valve morphology in these groups?
Thanks.

Randy
Foot Doctor


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News